Markets & Finance

CS First Boston Lowers Myriad Genetics to 'Neutral'

Credit Suisse First Boston downgraded Myriad Genetics (MYGN) to neutral from outperform.

Analyst Mark Augustine says the fourth-quarter results were disappointing. He notes predictive medicine sales are up 22% year over year, but essentially flat sequentially. Augustine widened the 86-cent fiscal 2004 (June) loss estimate to a $1.00 loss. He cut the $14 to $16 target range to $11 to $13.

He says he's waiting for benefits to emerge from a DTC campaign that ended earlier this year. Also, Augustine notes the critical-to-long-term predictive medicine uptake will be supportive clinical studies that could help establish optimal ways to manage individuals at increased risk for breast and ovarian cancer.

The Good Business Issue

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

blog comments powered by Disqus